Clinical trials: Pembrolizumab
Solid Tumors
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer…
- Trial name
- NCT07415031
- Testing
- Adagrasib, Pembrolizumab, Cetuximab
- Where
- 102 sites in United States, Australia and 19 more
- Volunteers
- 170 people
- Sponsor
- Mirati Therapeutics Inc.
Advanced Solid Tumor, Unresectable Solid Tumor
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a…
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- ABILITY-1 (NCT05086692)
- Testing
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Where
- 28 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Medicenna Therapeutics, Inc.
Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of…
- Conditions
- Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Trial name
- NCT04060342
- Testing
- GB1275, nab-paclitaxel and gemcitabine, pembrolizumab
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 61 people
- Sponsor
- GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Non-small Cell Lung Cancer
Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)
In this study, participants with programmed cell death ligand 1 (PD-L1)-positive non-small cell lung cancer (NSCLC) will be randomized to receive single agent pembrolizumab for up to 35 treatments or standard of care (SOC)…
- Trial name
- NCT02220894
- Testing
- pembrolizumab, carboplatin, paclitaxel
- Volunteers
- 1,274 people
- Sponsor
- Merck Sharp & Dohme LLC
Neoplasms
GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1)
This is a first time in human (FTIH), open-label, non-randomized, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary clinical activity of GSK3174998…
- Trial name
- NCT02528357
- Testing
- GSK3174998, Pembrolizumab
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 141 people
- Sponsor
- GlaxoSmithKline
Head and Neck Carcinoma, Adenoid Cystic Carcinoma
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non…
- Conditions
- Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT03556228
- Testing
- VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg)
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 242 people
- Sponsor
- VM Oncology, LLC
Relapsed or Refractory Acute Myeloid Leukemia
Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia
The primary objective of this study is to evaluate the safety and tolerability of AMG 330, administered in combination with pembrolizumab, in participants with relapsed or refractory acute myeloid leukemia (R/R AML).
- Trial name
- NCT04478695
- Testing
- AMG 330, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Amgen
Advanced Solid Tumor
Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-003 Delivered by Intravenous Injection in Patients with Advanced Solid…
- Trial name
- NCT07751042
- Testing
- STX-003, KEYTRUDA®
- Where
- 4 sites in United States, Australia
- Volunteers
- 220 people
- Sponsor
- Strand Therapeutics Inc.
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta/T1 achieved a complete response (CR) at 3 months.
- Trial name
- ABLE-22 (NCT06545955)
- Testing
- Nadofaragene Firadenovec, Gemcitabine, Docetaxel
- Where
- 80 sites in United States, Canada and 6 more
- Volunteers
- 250 people
- Sponsor
- Ferring Pharmaceuticals
Metastatic Non-small Cell Lung Cancer
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
This study is to assess the pharmacokinetics (PK) and safety of SC pembrolizumab formulated with berahyaluronidase alfa (MK-3475A) versus (vs) intravenous (IV) pembrolizumab (MK-3475), administered with chemotherapy in first line…
- Trial name
- NCT05722015
- Testing
- Pembrolizumab Formulated with Berahyaluronidase Alfa, Pemetrexed, Cisplatin
- Where
- 110 sites in United States, Argentina and 14 more
- Volunteers
- 377 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Male Subjects
Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male Subjects
to Compare the Pharmacokinetics and Safety of BAT3306 versus KEYTRUDA® Administered in Healthy Male Subjects
- Trial name
- NCT06111196
- Testing
- Recombinant Humanized Anti-PD-1 Monoclonal Antibody Solution for Injection, Pembrolizumab injection
- Where
- China
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Bio-Thera Solutions
Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal
Development and Analysis of a Stool Bank for Cancer Patients
This study is aimed at understanding the impact of gut microbiota on efficacy of cancer therapies, in particular checkpoint inhibitors, and using the resulting information to design microbial immunotherapies.
- Trial name
- NCT04291755
- Testing
- Pembrolizumab Injection
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Persephone Biosciences
Advanced Solid Tumors
A Phase 1 Study of ASKG315 in Patients With Advanced Solid Tumors
The study is a Phase 1, open-label, multicenter, dose escalation study to evaluate the safety, tolerability, PK and PD of ASKG315 as a single agent (Part 1) and in combination with pembrolizumab (Part 2) in patients with advanced…
- Trial name
- NCT05509985
- Testing
- ASKG315
- Where
- 2 sites in Australia
- Volunteers
- 100 people
- Sponsor
- AskGene Pharma, Inc.
Melanoma Metastatic, Melanoma, Skin
Observational Study of Patients With Advanced Melanoma (Skin Cancer) to Assess if IOpener®-Melanoma Test Can Predict Response to Immunotherapy.
The goal of this observational study is to assess whether the IOpener® melanoma test can assist treating physicians in deciding which therapy is most suitable for patients with skin cancer (advanced cutaneous melanoma).
- Conditions
- Melanoma Metastatic, Melanoma, Skin, Melanoma Stage III or IV, Melanoma Advanced
- Trial name
- COMO (NCT06784778)
- Testing
- PBMC Kinase Activity Profile
- Where
- 3 sites in Germany
- Volunteers
- 196 people
- Sponsor
- Pamgene International B.V.
HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC
Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma
This is a multi-center study in patients with un-resectable Recurrent or Metastatic HPV16-positive oropharyngeal Head and Neck Squamous Cell Carcinoma (HNSCC).
- Trial name
- NCT06016920
- Testing
- VB10.16, Pembrolizumab
- Where
- 12 sites in France, Germany and 5 more
- Volunteers
- 110 people
- Sponsor
- Nykode Therapeutics ASA
Diffuse Large B-cell Lymphoma
Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients
A multi-center, open-label, phase Ib study to evaluate the safety and efficacy of the administration of tisagenlecleucel in combination with pembrolizumab in patients with r/r DLBCL who have received 2 or more lines of systemic…
- Trial name
- PORTIA (NCT03630159)
- Testing
- Tisagenlecleucel, Pembrolizumab
- Where
- 5 sites in United States, Austria and 1 more
- Volunteers
- 12 people
- Sponsor
- Novartis Pharmaceuticals
Small-cell Lung Cancer
Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer
The main purpose of this Phase 1/2 study is to determine the safety and efficacy of pegzilarginase in combination with pembrolizumab in patients with ED-SCLC who have relapsed or progressive disease on or within 6 months of…
- Trial name
- NCT03371979
- Testing
- Pegzilarginase, Pembrolizumab
- Where
- 22 sites in United States, Puerto Rico
- Volunteers
- 68 people
- Sponsor
- Aeglea Biotherapeutics
Colorectal Cancer, Gastric Cancer
Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis
This is an open, single arm, multicenter phase 2 trial in which BO-112 will be administered intratumorally in combination with intravenous pembrolizumab in patients with liver metastasis from colorectal, gastric or…
- Conditions
- Colorectal Cancer, Gastric Cancer, Oesophageal Cancer
- Trial name
- NCT04508140
- Testing
- Hepatic Biopsy, BO-112 with pembrolizumab
- Where
- 12 sites in Belgium, Italy and 1 more
- Volunteers
- 18 people
- Sponsor
- Highlight Therapeutics
Non-Small Cell Lung Cancer
Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors
This study is to assess the safety and tolerability, and to assess the preliminary clinical benefit of NKTR-214 when combined with pembrolizumab (KEYTRUDA®) with or without chemotherapy.
- Trial name
- PROPEL (NCT03138889)
- Testing
- NKTR-214, Pembrolizumab, Cisplatin
- Where
- 38 sites in United States, Australia and 3 more
- Volunteers
- 162 people
- Sponsor
- Nektar Therapeutics
Breast Cancer
Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC
CONTESSA TRIO is a multi-cohort, multicenter, Phase 2 study of tesetaxel, an investigational, orally administered taxane, in patients with metastatic breast cancer (MBC).
- Trial name
- CONTESSA TRIO (NCT03952325)
- Testing
- Tesetaxel, Nivolumab, Pembrolizumab
- Where
- 12 sites in United States, Singapore and 1 more
- Volunteers
- 294 people
- Sponsor
- Odonate Therapeutics, Inc.